Kanser Tedavilerine Bağlı Cilt Toksisitesi

Ra HS, Shin SJ, Kim JH, Lim H, Cho BC, Roh MR. The impact of dermatological toxicities of anti-cancer therapy on the dermatological quality of life of cancer patients. J Eur Acad Dermatol Venereol. 2013 Jan;27(1):e53-59.

Ladwa R, Fogarty G, Chen P, Grewal G, McCormack C, Mar V, et al. Management of Skin Toxicities in Cancer Treatment: An Australian/New Zealand Perspective. Cancers [Internet]. 2024 Jan [cited 2024 Dec 22];16(14):2526. Available from: https://www.mdpi.com/2072-6694/16/14/2526

Ulrich J, Hartmann JT, Dörr W, Ugurel S. Skin toxicity of anti-cancer therapy. J Dtsch Dermatol Ges. 2008 Nov;6(11):959–77.

Wyatt AJ, Leonard GD, Sachs DL. Cutaneous reactions to chemotherapy and their management. Am J Clin Dermatol. 2006;7(1):45–63.

Ener RA, Meglathery SB, Styler M. Extravasation of systemic hemato-oncological therapies. Ann Oncol. 2004 Jun;15(6):858–62.

Pérez Fidalgo JA, García Fabregat L, Cervantes A, Margulies A, Vidall C, Roila F, et al. Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. Ann Oncol. 2012 Oct;23 Suppl 7:vii167-173.

Jacobson JO, Polovich M, Gilmore TR, Schulmeister L, Esper P, Lefebvre KB, et al. Revisions to the 2009 american society of clinical oncology/oncology nursing society chemotherapy administration safety standards: expanding the scope to include inpatient settings. J Oncol Pract. 2012 Jan;8(1):2–6.

Nagore E, Insa A, Sanmartín O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot’) syndrome. Incidence, recognition and management. Am J Clin Dermatol. 2000;1(4):225–34.

Lorusso D, Di Stefano A, Carone V, Fagotti A, Pisconti S, Scambia G. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (“hand-foot” syndrome). Ann Oncol. 2007 Jul;18(7):1159–64.

Fabian CJ, Molina R, Slavik M, Dahlberg S, Giri S, Stephens R. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs. 1990 Feb;8(1):57–63.

Ek T, Jarfelt M, Mellander L, Abrahamsson J. Proinflammatory cytokines mediate the systemic inflammatory response associated with high-dose cytarabine treatment in children. Med Pediatr Oncol. 2001 Nov;37(5):459–64.

Forsberg SA. Scalp cooling therapy and cytotoxic treatment. Lancet. 2001 Apr 7;357(9262):1134.

Dreno B, Khosrotehrani K, De Barros Silva G, Wolf JR, Kerob D, Trombetta M, et al. The role of dermocosmetics in the management of cancer-related skin toxicities: international expert consensus. Support Care Cancer. 2023 Nov 4;31(12):672.

Riley P, Glenny AM, Worthington HV, Littlewood A, Clarkson JE, McCabe MG. Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy. Cochrane Database Syst Rev. 2015 Dec 23;2015(12):CD011552.

Elad S, Cheng KKF, Lalla RV, Yarom N, Hong C, Logan RM, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer [Internet]. 2020 Oct 1 [cited 2024 Dec 20];126(19):4423–31. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540329/

Peng Y, Li Q, Zhang J, Shen W, Zhang X, Sun C, et al. Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors. Biosci Trends. 2019 Jan 22;12(6):537–52.

Burtness B, Anadkat M, Basti S, Hughes M, Lacouture ME, McClure JS, et al. NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. J Natl Compr Canc Netw. 2009 May;7 Suppl 1:S5-21; quiz S22-24.

HER1/EGFR Inhibitor-Associated Rash: Future Directions for Management and Investigation Outcomes from the HER1/EGFR Inhibitor Rash Management Forum | The Oncologist | Oxford Academic [Internet]. [cited 2024 Dec 12]. Available from: https://academic.oup.com/oncolo/article/10/5/345/6387434?login=false

Belum VR, Fontanilla Patel H, Lacouture ME, Rodeck U. Skin toxicity of targeted cancer agents: mechanisms and intervention. Future Oncol. 2013 Aug;9(8):1161–70.

Shah DR, Shah RR, Morganroth J. Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy. Drug Saf. 2013 Jun;36(6):413–26.

Beech J, Germetaki T, Judge M, Paton N, Collins J, Garbutt A, et al. Management and grading of EGFR inhibitor-induced cutaneous toxicity. Future Oncol. 2018 Oct;14(24):2531–41.

Hofheinz RD, Lorenzen S, Trojan J, Ocvirk J, Ettrich TJ, Al-Batran SE, et al. EVITA-a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity. Ann Oncol. 2018 Apr 1;29(4):1010–5.

Eriksen JG, Kaalund I, Clemmensen O, Overgaard J, Pfeiffer P. Placebo-controlled phase II study of vitamin K3 cream for the treatment of cetuximab-induced rash. Support Care Cancer. 2017 Jul;25(7):2179–85.

Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, et al. Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer. JCO [Internet]. 2010 Mar 10 [cited 2024 Dec 12];28(8):1351–7. Available from: https://ascopubs.org/doi/10.1200/JCO.2008.21.7828

Reguiai Z, Bachet JB, Bachmeyer C, Peuvrel L, Beylot-Barry M, Bezier M, et al. Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithm. Support Care Cancer [Internet]. 2012 Jul 1 [cited 2024 Dec 12];20(7):1395–404. Available from: https://doi.org/10.1007/s00520-012-1451-6

Bjellerup M, Ljunggren B. Differences in phototoxic potency should be considered when tetracyclines are prescribed during summer-time. A study on doxycycline and lymecycline in human volunteers, using an objective method for recording erythema. Br J Dermatol. 1994 Mar;130(3):356–60.

Mandalà M, Massi D, De Giorgi V. Cutaneous toxicities of BRAF inhibitors: clinical and pathological challenges and call to action. Crit Rev Oncol Hematol. 2013 Nov;88(2):318–37.

Dummer R, Rinderknecht J, Goldinger SM. Ultraviolet A and photosensitivity during vemurafenib therapy. N Engl J Med. 2012 Feb 2;366(5):480–1.

Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012 Jan 19;366(3):207–15.

Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol. 2017 Jul 1;28(7):1631–9.

Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015 Jan 1;372(1):30–9.

Williams VL, Cohen PR, Stewart DJ. Sorafenib-induced premalignant and malignant skin lesions. Int J Dermatol. 2011 Apr;50(4):396–402.

Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018 May;19(5):603–15.

Anforth RM, Blumetti TCMP, Kefford RF, Sharma R, Scolyer RA, Kossard S, et al. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol. 2012 Nov;167(5):1153–60.

Sinha R, Edmonds K, Newton-Bishop JA, Gore ME, Larkin J, Fearfield L. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br J Dermatol. 2012 Nov;167(5):987–94.

Welsh SJ, Corrie PG. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther Adv Med Oncol [Internet]. 2015 Mar [cited 2024 Dec 13];7(2):122–36. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4346212/

Lacouture ME, Reilly LM, Gerami P, Guitart J. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol. 2008 Nov;19(11):1955–61.

McLellan B, Ciardiello F, Lacouture ME, Segaert S, Van Cutsem E. Regorafenib-associated hand–foot skin reaction: practical advice on diagnosis, prevention, and management. Ann Oncol [Internet]. 2015 Oct [cited 2024 Dec 13];26(10):2017–26. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4576906/

Anderson R, Jatoi A, Robert C, Wood LS, Keating KN, Lacouture ME. Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). Oncologist. 2009 Mar;14(3):291–302.

Huang WK, Hsu HC, Yang TS, Lu CW, Pan YR, Wu CE, et al. Zinc supplementation decreased incidence of grade ≥2 hand-foot skin reaction induced by regorafenib: A phase II randomized clinical trial. Eur J Cancer. 2023 Dec;195:113286.

Chen JC, Wang JC, Pan YX, Yi MJ, Chen JB, Wang XH, et al. Preventive effect of celecoxib in sorafenib-related hand-foot syndrome in hepatocellular carcinoma patients, a single-center, open-label, randomized, controlled clinical phase III trial. Am J Cancer Res. 2020;10(5):1467–76.

Manchen E, Robert C, Porta C. Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse. J Support Oncol. 2011;9(1):13–23.

Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J, et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist. 2008 Sep;13(9):1001–11.

Aparicio-Gallego G, Blanco M, Figueroa A, García-Campelo R, Valladares-Ayerbes M, Grande-Pulido E, et al. New Insights into Molecular Mechanisms of Sunitinib-Associated Side Effects. Molecular Cancer Therapeutics [Internet]. 2011 Dec 7 [cited 2024 Dec 13];10(12):2215–23. Available from: https://doi.org/10.1158/1535-7163.MCT-10-1124

Lacouture ME, Sibaud V, Anadkat MJ, Kaffenberger B, Leventhal J, Guindon K, et al. Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines. Oncologist [Internet]. 2021 Feb [cited 2024 Dec 13];26(2):e316–26. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873330/

Jfri A, Meltzer R, Mostaghimi A, LeBoeuf N, Guggina L. Incidence of Cutaneous Adverse Events With Phosphoinositide 3-Kinase Inhibitors as Adjuvant Therapy in Patients With Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2022 Oct 13;8(11):1635–43.

Sibaud V. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy. Am J Clin Dermatol. 2018 Jun;19(3):345–61.

Kawsar A, Hussain K, Muinonen-Martin AJ, Fearfield L. How to recognize and manage skin toxicities associated with immune checkpoint inhibitors: a practical approach. Br J Dermatol. 2023 Oct 30;189(Suppl 1):i3–10.

Phillips GS, Wu J, Hellmann MD, Postow MA, Rizvi NA, Freites-Martinez A, et al. Treatment Outcomes of Immune-Related Cutaneous Adverse Events. Journal of Clinical Oncology [Internet]. 2019 Oct 20 [cited 2024 Dec 14]; Available from: https://ascopubs.org/doi/10.1200/JCO.18.02141

TSIOGKA A, BAUER JW, PATSATSI A. Bullous Pemphigoid Associated with Anti-programmed Cell Death Protein 1 and Anti-programmed Cell Death Ligand 1 Therapy: A Review of the Literature. Acta Derm Venereol [Internet]. 2021 Jan 20 [cited 2024 Dec 14];101(1):1497. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309843/

Belum VR, Benhuri B, Postow MA, Hellmann MD, Lesokhin AM, Segal NH, et al. Characterization and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer [Internet]. 2016 Jun [cited 2024 Dec 14];60:12–25. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4998047/

Quesada S, Guichard A, Fiteni F. Cancer-Related Alopecia: From Etiologies to Global Management. Cancers (Basel). 2021 Nov 5;13(21):5556.

Sterkens A, Lambert J, Bervoets A. Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options. Clin Exp Med [Internet]. 2021 May 1 [cited 2024 Dec 14];21(2):215–30. Available from: https://doi.org/10.1007/s10238-020-00673-w

Rosenthal A, Israilevich R, Moy R. Management of acute radiation dermatitis: A review of the literature and proposal for treatment algorithm. J Am Acad Dermatol. 2019 Aug;81(2):558–67.

Burke G, Faithfull S, Probst H. Radiation induced skin reactions during and following radiotherapy: A systematic review of interventions. Radiography (Lond). 2022 Feb;28(1):232–9.

Ryan JL. Ionizing Radiation: The Good, the Bad, and the Ugly. Journal of Investigative Dermatology [Internet]. 2012 Mar 1 [cited 2024 Dec 14];132(3, Part 2):985–93. Available from: https://www.sciencedirect.com/science/article/pii/S0022202X15356608

Bray FN, Simmons BJ, Wolfson AH, Nouri K. Acute and Chronic Cutaneous Reactions to Ionizing Radiation Therapy. Dermatol Ther (Heidelb) [Internet]. 2016 Jun 1 [cited 2024 Dec 14];6(2):185–206. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4906114/

Wong RKS, Bensadoun RJ, Boers-Doets CB, Bryce J, Chan A, Epstein JB, et al. Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group. Support Care Cancer. 2013 Oct;21(10):2933–48.

Pignol JP, Olivotto I, Rakovitch E, Gardner S, Sixel K, Beckham W, et al. A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol. 2008 May 1;26(13):2085–92.

Shaitelman SF, Schlembach PJ, Arzu I, Ballo M, Bloom ES, Buchholz D, et al. Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation: A Randomized Clinical Trial. JAMA Oncol. 2015 Oct;1(7):931–41.

Jacobson G, Bhatia S, Smith BJ, Button AM, Bodeker K, Buatti J. Randomized trial of pentoxifylline and vitamin E vs standard follow-up after breast irradiation to prevent breast fibrosis, evaluated by tissue compliance meter. Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):604–8.